Tekrardan Hoşgeldiniz
Cointime’a Katıl
Giriş Yap
Kayıt Ol
Gelen kutunuzu kontrol edin
Plexision
About
Develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $218.39K
- Industries
- Biotechnology
- Founded date
- Jan 1, 2008
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders.Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells.Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh.Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 1, 2020 | Grant | $218.39K | 1 |
National Science Foundation
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
